← back to search

Bernhard Zimmermann

Natera (United States) · US
Area of research
Cancer Research · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Cancer Genomics and Diagnostics, Prenatal Screening and Diagnostics, Genetic factors in colorectal cancer, and Genomic variations and chromosomal abnormalities.
h-index
39
citations
9,808
works
147
NIH funding
primary concept
Medicine
email

Recent publications

A two-threshold algorithm using donor-derived cell-free DNA fraction and quantity to detect acute rejection after heart transplantation
American Journal of Transplantation 2025cited by 14position: contributordoi
A two-threshold algorithm using donor-derived cell-free DNA fraction and quantity to detect acute rejection after heart transplantation
American Journal of Transplantation 2025cited by 13position: middledoi
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
2024cited by 33position: contributordoi
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer
Gynecologic Oncology 2022cited by 74position: middledoi
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Nature 2021cited by 595position: middledoi
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases
JCO Precision Oncology 2021cited by 128position: middledoi
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
2021cited by 97position: contributordoi
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
npj Breast Cancer 2021cited by 52position: middledoi
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
2021cited by 46position: contributordoi
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Annals of Oncology 2020cited by 433position: middledoi
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
2020cited by 368position: contributordoi
Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival
2020cited by 1position: contributordoi
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
2019cited by 717position: contributordoi
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
2019cited by 395position: contributordoi
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
2019cited by 386position: contributordoi
Analytical Validation of a Single-nucleotide Polymorphism-based Donor-derived Cell-free DNA Assay for Detecting Rejection in Kidney Transplant Patients.
2019cited by 43position: contributordoi
Isolation of Cell-Free DNA from Maternal Plasma.
2019cited by 5position: contributordoi
Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR
Journal of Clinical Medicine 2018cited by 208position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alexey Aleshin · Natera (United States)5 papers (2020–2024) · 5 papers (2020–2025)Paul R. Billings · General Dynamics (United States)4 papers (2018–2021)Himanshu Sethi · Natera (United States)3 papers (2020–2022)Christina Yau · Buck Institute for Research on Aging3 papers (2020–2021)Matthew Rabinowitz · Natera (United States)3 papers (2019–2025)A. Jo Chien · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2020–2021)Fotios Loupakis · University of Florence2 papers (2021–2021)Ekaterina Kalashnikova · Natera (United States)2 papers (2021–2022)Amy L. Delson · University of California, San Francisco2 papers (2020–2021)Jacqui Shaw · University of Leicester2 papers (2019–2024)Mark Jesus M. Magbanua · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2020–2021)Laura J. Esserman · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2020–2021)Gillian L. Hirst · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2020–2021)Svetlana Shchegrova · Natera (United States)2 papers (2020–2021)Paul Kim · Profectus Biosciences (United States)2 papers (2025–2025)Debu Tripathy · The University of Texas MD Anderson Cancer Center2 papers (2020–2021)Lars Dyrskjøt · Icahn School of Medicine at Mount Sinai2 papers (2019–2019) · 2 papers (2021–2024)Justin Stebbing · Renmin Hospital of Wuhan University2 papers (2019–2024)